Blue Jet Healthcare Limited has informed the Exchange regarding Outcome of Board Meeting held on May 14, 2025.
BLUEJET · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.8 pts less than Nifty Smallcap 250 and 0.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Blue Jet Healthcare's board approved audited FY25 results showing revenue from operations of ₹10,299.85 million, up about 45% from ₹7,115.98 million in FY24, while profit after tax jumped roughly 86% to ₹3,052.03 million (vs ₹1,637.51 million). The board recommended a final dividend of ₹1.2 per share (60%) on a face value of ₹2, subject to shareholder approval. It also approved a proposal to raise up to ₹15,000 million through QIP, preferential issue, private placement or a combination, subject to approvals. The company acquired a 30,366 sq meter industrial plot at Dahej III, Gujarat from GIDC for about ₹11.12 crore for manufacturing expansion. Statutory auditor KKC & Associates LLP issued an unmodified opinion, though the results note an income tax demand of ₹1,933.86 million (including ₹646.44 million interest) for AY 2020-21 to 2023-24 currently under appeal.
Strong top-line and bottom-line growth along with a healthy dividend are positives for shareholders, but the proposed ₹15,000 million capital raise may lead to equity dilution depending on the instrument mix. The pending income tax demand of nearly ₹1,934 million remains a material overhang, though the company believes it has a strong case on appeal.